LAKEWOOD-AMEDEX BIOTHERAPEUT
LABTNASDAQπ #5327 by market capEarnings Feb 15US Equity
$0.24β² $0.03 (+15.03%)
Market closed Β· at closeTrack LABT
Get earnings, price moves & breaking news on Telegram
24hβ² 15.0%
7dβΌ 11.9%
14dβΌ 34.0%
30dβΌ 22.0%
ytdβ
1yβ
π¦Market Cap
$428,736
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $0.22 β $0.31
- 52-Week Range
- $0.17 β $98.20
- Volume (shares)
- 57,668,019
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.8M
- Next Earnings
- 2027-02-15
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.90
- Dividend Yield
- 0.00%
LAKEWOOD-AMEDEX BIOTHERAPEUT
LABTFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$4MβΌ β6.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
191K
About LAKEWOOD-AMEDEX BIOTHERAPEUT
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.